Voyager Q2 FY26 net loss narrows to $24.47 million; revenue falls to $3.17 million

Reuters2026/08/06 20:06

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Voyager posted a Q2 net loss of USD 24.5 million, narrowing from USD 33.4 million a year earlier.
Revenue fell 39.1% from a year earlier to USD 3.2 million, on lower Neurocrine collaboration revenue as activities moved beyond research.
R&D expenses dropped 29.7% to USD 22 million, reflecting program and platform prioritization.
Cash, cash equivalents, and marketable securities totaled USD 148.8 million at June 30, with runway projected into 2028.
VY7523 tau PET imaging data are expected in Q4 2026; VY1706 dosing is expected to begin in Q4 2026 after FDA IND clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061601PRIMZONEFULLFEED9804868) on August 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Voyager Q2 FY26 net loss narrows to $24.47 million; revenue falls to $3.17 million

You may also like

Crypto prices